Summary of key issues raised in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) meeting

Amit Baumel; Justin Baker; Michael L. Birnbaum; Helen Christensen; Munmun De Choudhury; David C. Mohr; Fred Muench; Danielle Schlosser; Nick Titov; John M. Kane

doi:10.1176/appi.ps.201700270

Summary of key issues raised in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) meeting

Amit Baumel, Justin Baker, Michael L. Birnbaum, Helen Christensen, Munmun De Choudhury, David C. Mohr, Fred Muench, Danielle Schlosser, Nick Titov, John M. Kane

Department of Community Mental Health

Research output: Contribution to journal › Article › peer-review

Abstract

Technology provides an unparalleled opportunity to remove barriers to earlier identification and engagement in services for mental and addictive disorders by reaching people earlier in the course of illness and providing links to just-intime, cost-effective interventions. Achieving this opportunity, however, requires stakeholders to challenge underlying assumptions about traditional pathways to mental health care. In this Open Forum, the authors highlight key issues discussed in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) meeting-held October 13-14, 2016, in New York City-that are related to three identified areas in which technology provides important and unique opportunities to advance early identification, increase service engagement, and decrease the duration of untreated mental and addictive disorders.

Original language	English
Pages (from-to)	590-592
Number of pages	3
Journal	Psychiatric Services
Volume	69
Issue number	5
DOIs	https://doi.org/10.1176/appi.ps.201700270
State	Published - 1 May 2018

Bibliographical note

Funding Information:
The TEAAM-I meeting was supported by grants MH090590 and 5R34MH103835-02 from the National Institute of Mental Health (NIMH) to Dr. Kane and by NIMH travel support for grantees. Support for the meeting was also received from Verily Life Sciences, Donald and Barbra Zucker, and The Zucker Hillside Hospital and Northwell Health.

Funding Information:
Dr. Baker reports receipt of consulting fees from Pear Therapeutics. Dr. Mohr reports receipt of honoraria from Optum Behavioral Health and ownership interest in Actualize Therapy. Dr. Schlosser has a financial interest in and is an employee of Verily Life Sciences. Dr. Kane reports receipt of consulting fees, honoraria, or grant support from or participation in advisory boards for Alkermes, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest (Allergan), Genentech, Intracellular Therapies, Janssen Pharmaceutica, Johnson and Johnson, Lundbeck, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda, and Teva; he reports being a shareholder in LB Pharmaceuticals and Vanguard Research Group. The other authors report no financial relationships with commercial interests.

Publisher Copyright:
© American Psychiatric Association. All rights reserved.

ASJC Scopus subject areas

Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1176/appi.ps.201700270

Cite this

@article{14541d51cf1e47dab7180b60620f014c,

title = "Summary of key issues raised in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) meeting",

abstract = "Technology provides an unparalleled opportunity to remove barriers to earlier identification and engagement in services for mental and addictive disorders by reaching people earlier in the course of illness and providing links to just-intime, cost-effective interventions. Achieving this opportunity, however, requires stakeholders to challenge underlying assumptions about traditional pathways to mental health care. In this Open Forum, the authors highlight key issues discussed in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) meeting-held October 13-14, 2016, in New York City-that are related to three identified areas in which technology provides important and unique opportunities to advance early identification, increase service engagement, and decrease the duration of untreated mental and addictive disorders.",

author = "Amit Baumel and Justin Baker and Birnbaum, {Michael L.} and Helen Christensen and {De Choudhury}, Munmun and Mohr, {David C.} and Fred Muench and Danielle Schlosser and Nick Titov and Kane, {John M.}",

note = "Funding Information: The TEAAM-I meeting was supported by grants MH090590 and 5R34MH103835-02 from the National Institute of Mental Health (NIMH) to Dr. Kane and by NIMH travel support for grantees. Support for the meeting was also received from Verily Life Sciences, Donald and Barbra Zucker, and The Zucker Hillside Hospital and Northwell Health. Funding Information: Dr. Baker reports receipt of consulting fees from Pear Therapeutics. Dr. Mohr reports receipt of honoraria from Optum Behavioral Health and ownership interest in Actualize Therapy. Dr. Schlosser has a financial interest in and is an employee of Verily Life Sciences. Dr. Kane reports receipt of consulting fees, honoraria, or grant support from or participation in advisory boards for Alkermes, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest (Allergan), Genentech, Intracellular Therapies, Janssen Pharmaceutica, Johnson and Johnson, Lundbeck, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda, and Teva; he reports being a shareholder in LB Pharmaceuticals and Vanguard Research Group. The other authors report no financial relationships with commercial interests. Publisher Copyright: {\textcopyright} American Psychiatric Association. All rights reserved.",

year = "2018",

month = may,

day = "1",

doi = "10.1176/appi.ps.201700270",

language = "English",

volume = "69",

pages = "590--592",

journal = "Psychiatric Services",

issn = "1075-2730",

publisher = "American Psychiatric Association",

number = "5",

}

TY - JOUR

T1 - Summary of key issues raised in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) meeting

AU - Baumel, Amit

AU - Baker, Justin

AU - Birnbaum, Michael L.

AU - Christensen, Helen

AU - De Choudhury, Munmun

AU - Mohr, David C.

AU - Muench, Fred

AU - Schlosser, Danielle

AU - Titov, Nick

AU - Kane, John M.

N1 - Funding Information: The TEAAM-I meeting was supported by grants MH090590 and 5R34MH103835-02 from the National Institute of Mental Health (NIMH) to Dr. Kane and by NIMH travel support for grantees. Support for the meeting was also received from Verily Life Sciences, Donald and Barbra Zucker, and The Zucker Hillside Hospital and Northwell Health. Funding Information: Dr. Baker reports receipt of consulting fees from Pear Therapeutics. Dr. Mohr reports receipt of honoraria from Optum Behavioral Health and ownership interest in Actualize Therapy. Dr. Schlosser has a financial interest in and is an employee of Verily Life Sciences. Dr. Kane reports receipt of consulting fees, honoraria, or grant support from or participation in advisory boards for Alkermes, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest (Allergan), Genentech, Intracellular Therapies, Janssen Pharmaceutica, Johnson and Johnson, Lundbeck, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda, and Teva; he reports being a shareholder in LB Pharmaceuticals and Vanguard Research Group. The other authors report no financial relationships with commercial interests. Publisher Copyright: © American Psychiatric Association. All rights reserved.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Technology provides an unparalleled opportunity to remove barriers to earlier identification and engagement in services for mental and addictive disorders by reaching people earlier in the course of illness and providing links to just-intime, cost-effective interventions. Achieving this opportunity, however, requires stakeholders to challenge underlying assumptions about traditional pathways to mental health care. In this Open Forum, the authors highlight key issues discussed in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) meeting-held October 13-14, 2016, in New York City-that are related to three identified areas in which technology provides important and unique opportunities to advance early identification, increase service engagement, and decrease the duration of untreated mental and addictive disorders.

AB - Technology provides an unparalleled opportunity to remove barriers to earlier identification and engagement in services for mental and addictive disorders by reaching people earlier in the course of illness and providing links to just-intime, cost-effective interventions. Achieving this opportunity, however, requires stakeholders to challenge underlying assumptions about traditional pathways to mental health care. In this Open Forum, the authors highlight key issues discussed in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) meeting-held October 13-14, 2016, in New York City-that are related to three identified areas in which technology provides important and unique opportunities to advance early identification, increase service engagement, and decrease the duration of untreated mental and addictive disorders.

UR - http://www.scopus.com/inward/record.url?scp=85046347865&partnerID=8YFLogxK

U2 - 10.1176/appi.ps.201700270

DO - 10.1176/appi.ps.201700270

M3 - Article

C2 - 29334875

AN - SCOPUS:85046347865

SN - 1075-2730

VL - 69

SP - 590

EP - 592

JO - Psychiatric Services

JF - Psychiatric Services

IS - 5

ER -

Summary of key issues raised in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) meeting

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this